ESMO 2023: Pembrolizumab Improves PFS With Standard Treatment in HER2-Positive Gastroesophageal Cancer
Treatment can be considered for first-line therapy in patients with PD-L1 overexpression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.